Generic Medicine Info
Indications and Dosage
Chronic diarrhoea
Adult: As oral solution: Initially, 4-8 mg daily in divided doses, may be adjusted depending on the severity. Doses may be given bid when patient’s daily maintenance dose is established. Max: 16 mg daily.

Acute diarrhoea
Adult: As cap, orodispersible tab: Initially, 4 mg, followed by 2 mg after each loose stool. Usual dose: 6-8 mg daily. Max: 12 mg daily. As oral solution: Initially, 4 mg, followed by 2 mg after each loose stool. Max dose: 16 mg daily. Investigate cause of diarrhoea if clinical improvement is not observed within 2 days.
Child: As cap, orodispersible tab: ≥12 years Same as adult dose. As oral solution: 4-8 years 1 mg 3 or 4 times daily for up to 3 days. >8-12 years 2 mg 4 times daily for up to 5 days. Investigate cause of diarrhoea if clinical improvement is not observed within 2 days.
May be taken with or without food.
Conditions when peristalsis inhibition should be avoided (e.g. constipation, abdominal distension, ileus). Acute ulcerative colitis, acute dysentery characterised by bloody stools and high fever, bacterial enterocolitis caused by Salmonella, Shigella, and Campylobacter; antibiotic-associated colitis, abdominal pain without diarrhoea. Children <4 years (oral solution); <12 years (cap, orodispersible tab); <18 years (patient with irritable bowel syndrome).
Special Precautions
Patients with AIDS, glaucoma, urinary bladder neck obstruction, pyloric obstruction, significant gastric retention, or intestinal statis, risk factors for QT interval prolongation (e.g. congenital long QT syndrome, history of cardiac arrhythmias or other heart conditions, electrolyte abnormalities). Not recommended for long-term treatment. Hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Ileus, constipation, abdominal distension, abdominal pain, bloody stool, syncope, ventricular tachycardia.
Eye disorders: Rarely, miosis.
Gastrointestinal disorders: Flatulence, nausea, dyspepsia, dry mouth, vomiting.
General disorders and admin site conditions: Rarely, fatigue.
Immune system disorders: Rarely, urticaria, angioedema.
Musculoskeletal and connective tissue disorders: Hypertonia.
Nervous system disorders: Headache, dizziness, somnolence, stupor, depressed level of consciousness, loss of consciousness, coordination abnormality.
Renal and urinary disorders: Rarely, urinary retention.
Skin and subcutaneous tissue disorders: Rash. Rarely, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Potentially Fatal: Megacolon, toxic megacolon, cardiac events e.g. QT interval and QRS complex prolongation, torsades de pointes, cardiac arrest. Rarely, anaphylaxis and anaphylactic shock.
Patient Counseling Information
This drug may cause dizziness, drowsiness, or tiredness, or depressed level of consciousness, if affected, do not drive or operate machinery.
Monitoring Parameters
Assess for the cause of diarrhoea prior to treatment. Monitor for signs of CNS toxicity (in patients with hepatic impairment).
Symptoms: CNS depression (stupor, coordination abnormality, somnolence, miosis, muscular hypertonia and respiratory depression), constipation, urinary retention, ileus, or cardiac events like syncope, QT interval and QRS complex prolongation, torsades de pointes, other serious ventricular arrhythmias, and cardiac arrest. Management: If vomiting has occurred spontaneously, administration of activated charcoal. If vomiting has not occurred, may perform gastric lavage followed by administration of activated charcoal through gastric tube. Administer repeated treatment of naloxone as an antidote if CNS symptoms occur. Monitor patient closely for at least 48 hours to detect possible CNS depression.
Drug Interactions
Increased plasma concentrations with quinidine, ritonavir, gemfibrozil, ketoconazole, and itraconazole. May increase plasma levels of oral desmopressin. May enhance the QTc prolongation and ventricular arrhythmia of QT-prolonging agents.
Description: Loperamide, an opioid agonist, binds to the opioid receptor directly in the gut wall on the circular and longitudinal intestinal muscles thereby, reduces propulsive peristalsis and prolong transit time, and enhances resorption of water and electrolytes. It also increases the tone on the anal sphincter.
Absorption: Poorly absorbed in the gastrointestinal tract. Bioavailability: Approx 0.3%. Time to peak plasma concentration: 2.5 (oral solution); approx 5 hours (cap).
Distribution: Poorly distributed into the brain. Enters breast milk (small amounts). Plasma protein binding: Approx 95%, mainly to albumin.
Metabolism: Almost completely metabolised in the liver via oxidative N-demethylation mainly by CYP2C8 and CYP3A4 isoenzymes, and to a lesser extent by CYP2B6 and CYP2D6 isoenzymes to form desmethylloperamide. Undergoes significant first-pass effect.
Excretion: Mainly via faeces (as unchanged drug and metabolites); urine. Elimination half-life: Approx 10 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3955, Loperamide. https://pubchem.ncbi.nlm.nih.gov/compound/Loperamide. Accessed May 26, 2022.

Store between 20-25°C.
MIMS Class
ATC Classification
A07DA03 - loperamide ; Belongs to the class of antipropulsives. Used in the treatment of diarrhea.
Anon. Loperamide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/07/2019.

Buckingham R (ed). Loperamide Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/07/2019.

Imodium 1 mg/5 mL Oral Solution (Janssen-Cilag Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 03/07/2019.

Imodium Instant Melts (McNeil Products Limited). MHRA. https://products.mhra.gov.uk. Accessed 03/07/2019.

Loperamide 2 mg Capsules (Teva UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 03/07/2019.

Loperamide Hydrochloride Solution (Rite Aid Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 03/07/2019.

Mylan New Zealand Ltd. Diamide 2 mg Capsules data sheet 30 January 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 03/07/2019.

Disclaimer: This information is independently developed by MIMS based on Loperamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
  • Bryper
  • Diaperyl
  • Diastop
  • Doctor's Loperamide
  • Gastromed
  • Imodium
  • Lodarest
  • Lomotil
  • Loniper
  • Lopran
  • RiteMED Loperamide
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in